These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 16673206)

  • 1. Restoration of transforming growth factor-beta type II receptor reduces tumorigenicity in the human adrenocortical carcinoma SW-13 cell line.
    Yamamoto N; Imai J; Watanabe M; Hiroi N; Sugano S; Yoshino G
    Horm Metab Res; 2006 Mar; 38(3):159-66. PubMed ID: 16673206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis.
    Guo Y; Kyprianou N
    Cancer Res; 1999 Mar; 59(6):1366-71. PubMed ID: 10096572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of transforming growth factor beta type I receptor abolishes malignant phenotype of a rat bladder carcinoma cell line.
    Okamoto M; Oyasu R
    Cell Growth Differ; 1997 Aug; 8(8):921-6. PubMed ID: 9269901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
    Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
    Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of transforming growth factor-beta receptor type II and tumorigenicity in human breast adenocarcinoma MCF-7 cells.
    Ko Y; Banerji SS; Liu Y; Li W; Liang J; Soule HD; Pauley RJ; Willson JK; Zborowska E; Brattain MG
    J Cell Physiol; 1998 Aug; 176(2):424-34. PubMed ID: 9648930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation.
    Rowland-Goldsmith MA; Maruyama H; Kusama T; Ralli S; Korc M
    Clin Cancer Res; 2001 Sep; 7(9):2931-40. PubMed ID: 11555612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of transforming growth factor (TGF) beta1 type II receptor restores TGF-beta1 sensitivity and signaling in human prostate cancer cells.
    Guo Y; Kyprianou N
    Cell Growth Differ; 1998 Feb; 9(2):185-93. PubMed ID: 9486855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential responsiveness to autocrine and exogenous transforming growth factor (TGF) beta1 in cells with nonfunctional TGF-beta receptor type III.
    Deng X; Bellis S; Yan Z; Friedman E
    Cell Growth Differ; 1999 Jan; 10(1):11-8. PubMed ID: 9950213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contextual effects of transforming growth factor beta on the tumorigenicity of human colon carcinoma cells.
    Ye SC; Foster JM; Li W; Liang J; Zborowska E; Venkateswarlu S; Gong J; Brattain MG; Willson JK
    Cancer Res; 1999 Sep; 59(18):4725-31. PubMed ID: 10493532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of expression of TGF-beta1, TbetaRI, and TbetaRII correlates with differentiation in human oral squamous cell carcinomas.
    Mincione G; Di Marcantonio MC; Artese L; Vianale G; Piccirelli A; Piccirilli M; Perrotti V; Rubini C; Piattelli A; Muraro R
    Int J Oncol; 2008 Feb; 32(2):323-31. PubMed ID: 18202754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition.
    Parekh TV; Gama P; Wen X; Demopoulos R; Munger JS; Carcangiu ML; Reiss M; Gold LI
    Cancer Res; 2002 May; 62(10):2778-90. PubMed ID: 12019154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects.
    Tobin SW; Douville K; Benbow U; Brinckerhoff CE; Memoli VA; Arrick BA
    Oncogene; 2002 Jan; 21(1):108-18. PubMed ID: 11791181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transformation of intestinal epithelial cells by chronic TGF-beta1 treatment results in downregulation of the type II TGF-beta receptor and induction of cyclooxygenase-2.
    Sheng H; Shao J; O'Mahony CA; Lamps L; Albo D; Isakson PC; Berger DH; DuBois RN; Beauchamp RD
    Oncogene; 1999 Jan; 18(4):855-67. PubMed ID: 10023661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TGF-beta1 acts as a tumor suppressor of human malignant keratinocytes independently of Smad 4 expression and ligand-induced G(1) arrest.
    Paterson IC; Davies M; Stone A; Huntley S; Smith E; Pring M; Eveson JW; Robinson CM; Parkinson EK; Prime SS
    Oncogene; 2002 Feb; 21(10):1616-24. PubMed ID: 11896591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and characterization of DP-153, a nontumorigenic prostatic cell line that undergoes malignant transformation by expression of dominant-negative transforming growth factor beta receptor type II.
    Song K; Cornelius SC; Danielpour D
    Cancer Res; 2003 Aug; 63(15):4358-67. PubMed ID: 12907605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of responsiveness to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells.
    Tang B; de Castro K; Barnes HE; Parks WT; Stewart L; Böttinger EP; Danielpour D; Wakefield LM
    Cancer Res; 1999 Oct; 59(19):4834-42. PubMed ID: 10519393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of TGF-beta-regulated interleukin-8 expression in human prostate cancer cells.
    Lu S; Dong Z
    Prostate; 2006 Jun; 66(9):996-1004. PubMed ID: 16541418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma.
    Yang F; Strand DW; Rowley DR
    Oncogene; 2008 Jan; 27(4):450-9. PubMed ID: 17637743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of transforming growth factor-beta1 and transforming growth factor-beta Type-II receptor mRNA in papillary thyroid carcinoma.
    Matoba H; Sugano S; Yamaguchi N; Miyachi Y
    Horm Metab Res; 1998 Oct; 30(10):624-8. PubMed ID: 9851670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human malignant thyroid tumors displayed reduced levels of transforming growth factor beta receptor type II messenger RNA and protein.
    Lazzereschi D; Ranieri A; Mincione G; Taccogna S; Nardi F; Colletta G
    Cancer Res; 1997 May; 57(10):2071-6. PubMed ID: 9158007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.